Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
about
Belatacept for kidney transplant recipientsBelatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapyDysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for managementA Rationale for Age-Adapted Immunosuppression in Organ TransplantationDoes belatacept improve outcomes for kidney transplant recipients? A systematic reviewWhat's new in clinical solid organ transplantation by 2013.Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Belatacept and mediastinal histoplasmosis in a kidney transplant patient.Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.The need for minimization strategies: current problems of immunosuppression.Immunological risks of minimization strategies.Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair.Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.A safety evaluation of belatacept for the treatment of kidney transplant.Should belatacept be the centrepiece of renal transplantation?Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.Experience with belatacept rescue therapy in kidney transplant recipients.Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate.The faster the better: anastomosis time influences patient survival after deceased donor kidney transplantation.Co-stimulatory blockade with belatacept in kidney transplantation.Posttransplant Reduction in Pre-Existing Donor-Specific Antibody Levels After Belatacept- vs. Cyclosporine-Based Immunosuppression: Post-Hoc Analyses of BENEFIT and BENEFIT-EXT.Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.Recent advances in immunosuppression and acquired immune tolerance in renal transplants
P2860
Q24187867-ED2B0716-3E24-4BE8-ADAA-F24D37B31F66Q26745773-F25DB0C2-B849-4C1C-BD78-1FD03220110AQ26795773-918F3963-8F53-4E18-90D9-1EA2BD552ED5Q28080954-76DBA88F-826B-44CC-B5A2-890AEA303614Q28084644-F32FDE9B-2847-413A-819F-2ED3C0140169Q34761349-F879254F-19A1-466E-9EDD-AAE266F63E14Q36087779-F83CFA57-BACD-438A-9F5D-C12D6E3E59AFQ36835315-B1069C5B-E439-4E44-8D7C-E11EA127D5FDQ38241710-38003019-D620-47A9-AB33-5B74E464B449Q38370826-039364BA-B6C9-43FA-9030-A9FC5F1F1608Q38391150-49B96C96-F7E5-4EF0-B762-1FAFDA76B63EQ38658621-FE9F2811-7EDA-4199-86A4-8D7298F5EC79Q38675622-64EAA4F5-6295-4188-B24A-9F24338719E5Q38852360-679A4D5C-BD0F-483C-9BDD-3355B6B8E642Q38862002-2053DCA0-3403-4AD3-8F03-06B3EF0B3976Q39264020-60655392-05AC-4A2D-92E0-5961810B6D43Q39808031-93FDB207-2FD4-409F-95A6-4E2FB931954BQ40181170-9A698045-0B39-4C60-893C-D82DAFD20D2EQ40199984-55D55A79-2F55-4DAE-A99A-C5C00A931BE9Q40513558-7F94DD9D-B9A9-4622-9029-8E647CE27CDDQ40535860-3B5645F4-5454-42FB-8219-7C762B471718Q41626807-89644CCC-5EE4-446A-BC0C-43639804D3F6Q51294468-0E7C2198-2AE2-4016-8FC2-FA0C7C4A3C92Q51735601-17BDD54B-4905-4A1A-A8CD-8F9202144A96Q53803179-1EFAFC7A-AD30-46AF-A0B9-1189606594D7Q57701477-5103988F-084E-412E-A52D-817434A14C43
P2860
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@en
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@nl
type
label
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@en
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@nl
prefLabel
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@en
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
@nl
P2093
P2860
P356
P1476
Long-term exposure to belatacept in recipients of extended criteria donor kidneys
@en
P2093
B Charpentier
F Mühlbacher
L Rostaing
M Del C Rial
Y Vanrenterghem
P2860
P304
P356
10.1111/AJT.12459
P407
P577
2013-09-18T00:00:00Z